Our Predictions for the 2022 Pharma Industry
Summary: Catalent’s CEO John Chiminski and Endpoints News’ John Carroll have a virtual fireside chat discussing their predictions for what 2022 has in store for the biopharma industry.
Leveraging Catalent’s Integrated Network to Accelerate Spray Drying and Tableting Scale-Up
Learn how a biopharmaceutical company partnered with Catalent to develop and manufacture a commercially-viable, patient-friendly, stable tablet for a program intended to treat a disease that has unmet medical need.
Developing Optimised Formulations with Minimal Drug Substance
Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies.
Optimizing Oral Drug Delivery using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges
This article looks at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.
Xpress Pharmaceutics™
Summary: Integrated Development Offering to Facilitate Adaptive Trials & Accelerate Phase 1
Webinar-Preparing for Phase 1: Strategies for Success in Advancing your Drug to First-in-Human Trials
Summary: During this webinar, biopharma R&D professionals will review strategies for moving successfully and efficiently from preclinical studies to first-in-human trials. They will call upon their own experiences to provide advice that will help others in the industry navigate this crucial transition.
Outsourcing Pharma Manufacturing – Keys to Successful Technology Transfers
This article discusses a systematic approach to ensure tech transfers meet scheduled timelines.
Overcoming Manufacturing Challenges for Accelerated Drug Development
This executive summary provides expert insight on overcoming manufacturing challenges associated with expedited development programs.
Maintaining Drug Product Properties and Optimizing Late-Stage Manufacturing Efficiency
Summary: In this webinar, experts provide an overview of the latest trends in manufacturing of oral solid dosage form and discuss key considerations of transitioning an early-stage project to late-stage as well as technology transfer.
Mapping the Pathway to Designing Successful Treatments
This executive summary includes evidence on how the right guidance at the right time can help you create more successful treatments.
Highly Potent API Drug Product Development and Manufacturing Using Micronization Technology
Summary: This webinar will discuss how to classify HPAPIs in early development and share recommendations for safe product handling, from clinical manufacturing to commercialization.
Micronization Technology Solutions From Early Phase Development to Commercial Scale Manufacturing
Summary: Catalent is a global leader in pharmaceutical air jet milling micronization with more than 30 years’ experience delivering micronization solutions.
Concept to Dosing-Challenges in New Orphan Drugs
Summary: In this webinar a group of experienced cancer drug developers discusses key strategies in managing an orphan drug program.
A Guide to Drug Development of Challenging Molecules
Summary: This webinar discusses, key considerations of early drug development, molecule developability assessment, drug bioavailability and discussed the relationship between intracellular and transcellular permeability of beyond the Rule of Five drugs.
Inhalation-Nasal Delivery Technology, Quality by Design Processes and Outsourcing Considerations
Catalent leverages decades of experience in the development, evaluation and manufacture of inhalation products to advance and accelerate molecules, from early development through commercial manufacturing.
Using Zydis® ODT to Solve Delivery Challenges for Tolerogenic Vaccines
Summary: Using Zydis® orally dissolving tablet (ODT) platform from Catalent as a unique delivery route for allergy immunotherapies.
Proven Quality – Preventing Quality Issues During Drug Development
Summary: A growing number of drug launches have faltered at the final hour because manufacturing processes weren’t up to FDA standards. This webinar explores how drug developers can properly monitor quality throughout the clinical production process and fix any issues that arise—before the FDA brings out the red flags.
Biologics By Mouth-Leveraging Freeze-Dried Orally Disintegrating Tablets
Summary: Learn more about the role of oral dose delivery for tolerogenic vaccines, fast dissolving tablets and biological APIs.
Scale Up & Tech Transfer of Fluid Bed Coating Processes
Summary: This webinar provides an introduction and comparison of top-spray and bottom-spray fluid bed coating technologies and how to select the most appropriate technique to meet the target product profile.
Is My Molecule Suitable for an Orally Disintegrating Tablet?
Summary: While new drug products may benefit from ODT formulation beginning with product launch, ODT formulation can also play a role in life cycle management of approved products.
Effective Scale-Up and Technology Transfer Strategies for Spray Dried Pharma Products
Summary: In this webinar, learn from real world case studies about best practices and strategies to mitigate risks and ensure a successful tech transfer from development through to commercial scale spray drying of pharmaceutical products.
Pharmaceutical Outsourcing for Oral Development and Manufacturing
Summary: This eBook includes an overview of outsourcing trends in the oral solid dose market. Featured articles describe the robust market resulting from the demand for specialized dosage forms such as controlled release, pediatric and geriatric delivery vehicles.
OptiForm® Solution Suite Bio Capabilities Sheet
OptiForm® Solution Suite Bio is designed to rapidly screen biomolecules’ potential for a non-invasive delivery route.
Article: Industry Trend: Examining the Emergence of Unit- & Bi-Dose Nasal Sprays
Summary: Molecules that are limited by a slow onset of action, a suboptimal side-effect profile, or a complicated administration process, may be good candidates for adaptation to a unit- or…
Orally Inhaled & Nasal Drug Delivery – An Evolving Pipeline Creating New Opportunities
Catalent’s Carla Vozone discusses the significant inhalation trends including those in larger molecules and novel indications.
Selecting the Most Suitable Dosage Form Technology for the Oral Delivery of Lipid-Based Formulations
Summary: Lipid-based drug delivery systems have found widespread acceptance for development of drug products containing developability challenged APIs.
Exclusive Orphan Drugs Industry Survey Results Desire to Treat Rare Diseases Tempered by a Lack of Internal Expertise and Capability
Summary: Orphan drugs face obstacles that span from discovery to launch, largely because of small patient populations and limited markets for rare disease therapies.
OneXpress Solution Capabilities Sheet
Summary: OneXpress™ is a single integrated solution that provides the fastest pathway from clinical to commercial manufacturing.
Boosting Bioavailability- How Companies are Using Advanced Technologies to Formulate Complex Molecules
Summary: This infographic focuses on evolving technologies that help overcome bioavailability challenges enabling the formulation of more complex molecules.
OptiDose® Design Solution Capabilities Sheet
Summary: OptiDose Design Solution is a comprehensive drug design assessment consisting of a holistic review of the molecule, patient, and market considerations. Led by Catalent’s highly experienced team of scientific advisors, this evaluation assesses key drug design considerations that can help create more successful treatments for all stakeholders.
Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening
Read this case study to learn how a team of bioavailability experts at Catalent took a target molecule from early stage to Phase 1 in under nine months.
Reducing Inhalation Burden Through High-Dose, Carrier-Free Spray Dry Powders
Explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung regions.
Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)
Summary: This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets.
High Potency Containment from Early Phase to Commercial Scale Micronization
Summary: In this webinar, learn more about enabling micronization of potent and highly potent compounds across the different stages of oral drug development
Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules
Summary: Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.
Industry Trend: Examining the Emergence of Unit- & Bi-Dose Nasal Sprays
Summary: Molecules that are limited by a slow onset of action, a suboptimal side-effect profile, or a complicated administration process, may be good candidates for adaptation to a unit- or…
Use of PBPK Modeling for Predicting and Optimizing Controlled Release Dosage Forms
Summary: Experts will share how dissolution tools and PBPK modeling can help evaluate whether a molecule is suitable for controlled release applications.
Strategies to Optimize the Dosage Form Design Process to Create Better Treatments
Summary: Experts use case studies to demonstrate how the right guidance, at the right time, can help drug developers create better treatments.
Developing Optimal Formulations
Summary: API-sparing development techniques and identification of the appropriate scalable formulation technology to improve drug solubility and enhance oral bioavailability.
Integrated Approach to Spray Drying for Optimized Oral and Vaccine Formulations
Summary: In this webinar, an academic expert will discuss optimal design space parameters involved in developing spray dried dispersion of poorly soluble drugs for oral and vaccine delivery.
Is My Molecule Suitable for an Orally Disintegrating Tablet?
Summary: This webinar aims to provide clarity on the types of molecules suitable for an ODT format as well as the regulatory pathways for new and established therapies.
Amorphous and Co-Amorphous Systems for Poorly Soluble Drugs
Summary: This webinar provides an overview of co-amorphous research and its recent findings, particularly, the impact of low molecular weight excipient on developability, stability and solubility.
Importance of Pediatric Biopharmaceutics in Design and Manufacture of Pediatric Dose Forms
Summary: Learn about the current challenges in pediatric drug development programs including predicting oral absorption, and in vitro and in silico methods that can be applied to predict behavior in pediatric populations.
Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise
Summary: In this webinar, Catalent experts will explain how the phase appropriate expertise and technologies of the OneXpress™ Solution can help streamline development and manufacturing, speed up your program timelines and reduce risks to transform your science into a successful treatment.
What Makes Lipid Excipients So Special?
Summary: In this webinar, we explain why a lipid drug development platform can meet the need for speed to clinic and how the innovative lipid excipients and technologies could solve formulation challenges, optimizing bioavailability for early phase molecules, improve patient compliance and bring products faster to market.
Getting Your Molecule From Preclinical Dev to Phase I
Summary: Three early drug development experts present insights and techniques to help your clients get their molecules from preclinical to Phase 1 studies.
A Roadmap for Early Development to Commercial Manufacturing
Summary: Phase-appropriate CMC-related activities can facilitate the transition from early development through commercialization.
Mapping the Pathway to Designing Successful Treatments
Summary: Experts introduce Catalent’s new OptiDose™ Design Solution, an integrated dose form design strategy based on an analyzation of your molecule, patient, and market.
Strategies for Integrated Business, Regulatory, & Scientific Needs of CMC Clients
Summary: Drug development requires integrating multi-disciplinary business, regulatory and scientific activities. To successfully support a client’s program, it is imperative to provide advice and services that support all three in the context of a program’s goal. In this exclusive webinar presented by Jim Spavins…
Catalent’s Expanded Inhalation Offering
Summary: Catalent expands its inhalation platform through the acquisition of a Boston-area facility, providing spray drying, powder encapsulation and blister packaging for Dry Powder Inhaler (DPI) capsules.
Innovative Solutions to Meet the Complex Pharmaceutical Supply Challenges
Summary: Integrated approach from development to clinical and benefits of working with a single integrated provider.
Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules
Summary: The transition from early phase to late phase of a small molecule program plays a pivotal role in determining a program’s ultimate success. Early planning strategies can help minimize the burdens often faced in that transition. The implementation of modeling tools…
Quality by design-Considerations for Inhalation Product Development
This article discusses how quality by design (QbD) can be built into inhalation product development to ensure a drug and device are safe and effective.
Pharma Predictions for 2021
Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
From Candidate to Clinic: Strategies to Accelerate Your Molecule’s Development Path
The development of orally administered small molecules is more challenging as an many have poor aqueous solubility and bioavailability.
Roller Compaction: New Trends, Challenges and Solutions
This article discusses why roller compaction is a robust option when developing a tablet or capsule formulation.
Strategies for De-risking Early-Phase Oral Small Molecule Drug Development
Summary: Characterize lead molecules and develop the best pathway to bring them to Phase I studies and beyond.
Partnering for Success: Strategies to Mitigate Common Pitfalls in Early Drug Development
Summary: Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound…
Early Drug Development: Strategy and Solution
This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.
From Development to Commercialization: Overcoming Scale-Up Issues
Summary: Recorded at Manufacturing Chemist Live 2020, this presentation discusses some of the key issues to consider when planning for the scale-up of a small molecule development program.
Analyzing Product Formulation Using Raman Spectroscopy
Comparing the dissolution rates and pellet structure of branded Sporanox® with three similar generic products, raman spectroscopy revealed recrystallizing API slowed the dissolution rate.
NMR and Mass Spectrometry in Pharmaceutical Development
Nuclear Magnetic Resonance spectroscopy and Mass Spectrometry are powerful techniques for the characterization and quantification of compounds.
Principles of Raman Spectroscopy and Application to Pharmaceutical Development
Raman Spectroscopy is used for applications like polymorph identification, analysis of API form, & evaluation of component distribution within a formulation.
Discover the Latest Funding, Drug Development and Clinical Solutions Strategies
Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.
Derisking Orphan Drug Programs in 2020 and Beyond
Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.
Developing Optimal Formulations Using Biorelevant Predictive Tools and Advanced Bioavailability Enhancement Technologies
Summary: Low bioavailability can lead to development challenges. Advanced formulation expertise and technologies can increase the chance of success in the clinic.
Joint Comfort Softgel
Summary: Unique combo formula containing LONGVIDA® Curcumin Extract intended to support joint comfort.
Cognitive Support Softgel – Unique Supplement Featuring Neumentix™ Spearmint Phenolic Complex
Summary: Leveraging Catalent’s expert formulation and dose design capabilities, Kemin Industries has developed a new to the segment nutritional supplement which includes their proprietary phenolic complex Neumentix™ derived from spearmint.
Coated Softgels for Consumer Products
Summary: With over 80 years of global manufacturing expertise, Catalent has an extensive network of facilities to provide full service integrated softgel manufacturing and coating capabilities.
EasyBurst® Chewable Capsules
Summary: EasyBurst® chewable technology is an ideal platform to deliver active ingredients, without the need for water, using our advanced taste masked fills encapsulated in our proprietary softgel shells.
Softdrop™ Lozenges
Summary: SoftDrop™ technology can deliver multiple active ingredients in a single softgel lozenge.
Consumer VMS Product Library
Summary: As your innovation partner, we will help you address your consumers’ needs by leveraging our differentiated softgel technologies and robust product library to give your brand a competitive advantage in the market.
Interview: Fierce Pharma with Jeremie Trochu
Summary: Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, recently sat down for an interview…
Next-Generation Orphan Drug Delivery
Summary: Big Pharma used to ignore this segment of the market, but now developing orphan drugs to treat these rare diseases is an industry priority.
The Future of Orphan Drugs: Insights on the Current Market, Trends & Strategic Partnerships Driving Innovation
Summary: In this report, we will highlight the trends shaping the orphan-drug market, with a particular focus on expedited drug development. Expert insights on navigating development and manufacturing challenges with…
OneXpress™: Phase Appropriate Technology & Expertise from Development to Commercialization
Summary: OneXpress is a single integrated solution that provides the fastest pathway from clinical development to commercial manufacturing. By taking a proactive approach and assessing production considerations early in development, our teams…
Early Phase Solutions
Summary: Explore how you can leverage Catalent’s successful track record optimizing thousands of molecules, deep development expertise and broadest set of superior technologies to…
Catalent Spray Drying Technology: From Development to Manufacturing
Summary: Catalent offers end-to-end spray drying solutions from early-phase development through to clinical supply, and scale-up to commercial finished dose forms.
From Candidate to Clinic: Strategies to Accelerate Your Molecule’s Development Path
Summary: A fast, efficient development process can deliver the right clinical candidate, best formulation strategy, and optimal dosage form to Phase 1.
Strategies to Avoid Dangerous Pitfalls in Pharmaceutical Consulting
Summary: Learn the strategies to avoid costly pitfalls in pharmaceutical consulting and Gain inside tips on using CDMO’s to deliver solutions to your clients.
Optimizing Lipid-Based Formulation for Commercial Success
Summary: This 90-minute virtual workshop includes presentations from BASF and Catalent that demonstrate on how lipid-based drug softgel technology can provide formulators with an effective delivery…
Setting Up Your Small Molecule for Success: Formulation, PBPK Modeling and Regulatory Strategies in Early Clinical Trials
Summary: This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.
Reducing Risks In Early Drug Development: From Drug Candidate to Phase 1 Clinical Testing
Summary: Achieving success in early development is essential in progressing a drug molecule’s next milestone. Such pressure can often lead to the adoption of…
CMC Considerations for Successful Early Drug Development
Summary: This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success.
Phase Appropriate Expertise and Technologies to Accelerate Product Development to Commercialization
Summary: In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from early-phase development to late-phase manufacturing.
Preparing Your Drug for Clinical Success: Strategies and Considerations
Summary: View this webinar to learn about the key considerations for transitioning a molecule from discovery through clinical studies.
Based on Exclusive Survey: Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions
Summary: In this webinar, experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.
R&D Leadership During the Pandemic
Summary: R&D execs discuss how they’ve reorganized global teams, tapped new programs to fight COVID-19 and plan for the future after the pandemic.
Spray Drying for Bioavailability Enhancement
Summary: The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. Nearly 40% of the new chemical…
How to Effectively Work with a Development Partner – From a Consultant Standpoint
Summary: Hear from experienced industry colleagues on the latest tips that will help your clients avoid critical pitfalls in early development of their drugs to best leverage CDMO…
Patient-Focused Drug Design: Through the Lens of Real-World Case Studies, Clinical Evidence and Advanced Delivery Solutions
Summary: Join this webinar to discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes.
AAPS 2019: IV Infusion In-Use Compatibility of the Regulatory Hormone Melatonin
Summary: The chemical stability challenges associated with many small molecule active pharmaceutical ingredients (API) necessitate the need for parenteral options for drug delivery.
Small Molecule Analytical Services
Summary: This document provides both a high-level overview of Catalent’s stand-alone small molecule analytical services (on front), and a detailed list of services organized by functional area…
Strategies for Flexible Manufacturing
Summary: Pharmaceutical and biotechnology companies approach external development and manufacturing partners for solutions for their product’s specific needs. New products are increasingly…
Proven Bioavailability Enhancement Solutions for Scalable and Robust Products
Summary: Lipid formulation and spray-dried dispersions are widely used, and proven technologies to overcome bioavailability challenges for poorly soluble molecules. For selecting the…
How to Accelerate Early Drug Development in Oncology For Small Molecules and Biologics
Summary: Get an insight into what it takes to move a pre-clinical drug candidate to a Phase 1 clinical trial. The presentations will provide guidance on non-clinical and regulatory considerations…
Spray-Drying Process for Scale up and Commercialization
Summary: The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. In a recent Pharmaceutical…
Prepare Your Clients for Success: Tips and Strategies to Avoid Dangerous Pitfalls in Consulting
Summary: Determining a client’s primary goal is critical to guiding them through the development of their asset. Additionally, their primary focus will impact the strategy used to develop…
Rapid Developability Assessment of Early Phase Molecules: Parallel Screening of Enabling Technologies and Use of PBPK Modeling
Summary: Achieving success in early development is essential in progressing to your molecule’s next milestone. While solving solubility is a major hurdle to overcome in early development…
An Integrated Approach to Spray Drying: From Scale-up to Manufacturing
Summary: Spray-drying technology is one of the methods of manufacturing high-quality amorphous solid dispersions. The application of a phase-appropriate quality-by-design…
All Offerings
Summary: Catalyst + Talent. Our name combines these ideas. From drug and biologic development to delivery technologies and supply solutions, we are the catalyst for your…
Designing a Turnkey Orphan Drug Program
Summary: This Endpoints News webinar brings four experts who represent some of the key constituencies when developing a modern orphan program – from early research through approval.
Model to Predict Process Parameters for Scale-Up of Hot Melt Extrusion Process
Summary: Technology transfer and scale-up from a laboratory-scale to commercial-scale HME process require several in-depth empirical studies during product development. Without prior calculations and in-silico scale-up…
Planning for Successful Product Launches
Summary: There has been increased focus and efforts on developing treatments for diseases with smaller patient populations, diseases for which there are no currently approved treatments…
Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations
Summary: In this webinar, industry experts discuss the recent advances, challenges and considerations in pediatric drug development. Real-life examples presented by the experts…
A Roadmap for Early Development to Commercial Manufacturing
Summary: A key hurdle for any drug development program is bringing the drug to clinical studies. Astute companies strategize past this milestone and plan for clinical and regulatory success.
Drug Design and the Patient Journey
Summary: Patient-focused drug design can be a key factor in real-world therapeutic outcomes and business success. But if successful treatments should be created with patients in mind…
Placing Patients at the Center of Drug Design
Summary: Patient centricity has always been at the heart of the pharmaceutical industry. With rising costs of drugs and healthcare, there has been an increased focus on the topic. Poor patient acceptance and…
Optimizing Spray Drying Strategies for Commercial Pharmaceutical Manufacturing
Summary: The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility.
Solid Dispersions – A Versatile Formulation Strategy for Poorly Soluble Drugs
Summary: The influx of poorly soluble compounds into the drug development pipeline is likely to continue unabated. Solid dispersions provide a formulation technique that is…
Regulatory Support
Summary: Our regulatory team completes over 150 agency submissions each year, supporting all stages of the product lifecycle. We assign a dedicated…
About Catalent: More Products. Better Treatments. Reliably Supplied.
Summary: Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your…
Catalent: Softgel Encapsulation
Summary: Softgel technology is the commercially-proven choice for encapsulation of challenging compounds. In addition, softgel technology may enhance the bioavailability of your product to…
Improving Bioavailability with Softgel Technology
Summary: Softgel technology offers a number of technical benefits. Probably foremost is the improvement or enhanced bioavailability that’s often achievable with the Softgel dosage…
Catalent: A True Strategic Partner
Summary: Catalent is much more than just a vendor or a supplier. What we’re trying to provide is a true strategic partnership, to become an extension, if you like, of their organization, and that can…
Catalent: Our Commitment To Customers
Summary: Catalent’s promise to our customers is more products, better treatments, reliably supplied. That’s not just a tagline for us. Those are the internal behaviors by which we’re trying to live by so that…
Catalent: Customizable Innovative Solutions
Summary: Catalent is staying on top of innovation maintaining deep and strategic relationships with our customers and our partners. It is critical for Catalent to understand the…
Catalent: Integrated Solutions
Summary: Our brand is all around more products, better treatments, reliably supplied. In terms of more products, that’s very much around how do — how do we help companies to take more molecules…
Catalent: Reliably Supplied
Summary: At Catalent, when we talk about “reliably supplied,” it goes way beyond the obvious of making this week’s deliveries on time. It’s about having all the foundational elements in place…
Catalent: Why Catalent
Summary: Customers work with Catalent because they know that they can come to us and have their most difficult problems solved. They also come to us because there’s no other company out there…
Our Values
Summary: At Catalent, our culture is entrepreneurial and collaborative. Our employees possess a passion for exceeding customer’s expectations. We are focused on continuous improvement…
RP Scherer Softgel Technology for Superior Drug Delivery
Summary: As innovators of softgel technology, Catalent RP Scherer softgel brings more than 75 years of development expertise and manufacturing experience to the full spectrum of drug delivery…
How to Effectively Work with a Development Partner – From a Consultant Standpoint
Summary: Determining a client’s primary goal is critical to guiding them through the development of their asset. Three experienced industry colleagues recently presented on the latest tips…
The World’s Leading Pharmaceutical Partner | Now on the NYSE
Summary: Whether you are looking for a single, tailored solution or multiple answers throughout your product’s lifecycle, we can improve the total value of your treatment – from discovery…
Behind the Scenes: Catalent IPO on the NYSE
Summary: On July 31, 2014, Catalent officially listed on the NYSE. Take a look behind the scenes at the NYSE on listing and closing bell day.
Catalent Micron Technologies Overview
Summary: Micron Technologies adds to Catalent’s long history of innovation and leadership in the pharmaceutical industry, with its proven and versatile portfolio of particle size reduction, micronization and milling…
Catalent Micron Technologies A Global Leader in Micronization Services
Summary: Catalent Micron Technologies is a leading international provider of particle size reduction and analytical services. We deliver first-class pharmaceutical contract micronization, milling…
Potent Capabilities for Micronization
Summary: Not only are we able to micronize compounds with air jet mills under full containment, but we have also developed containment solutions for several other types of milling equipment…
What is Micronization?
Summary: Particle size reduction is achieved through the use of fluid energy jet mills. The material is drawn into a confined, circular chamber by way of pressurized nitrogen gas or compressed…
Analytical Services & Capabilities | Why Catalent?
Summary: From discovery candidates to clinical trial materials to regulatory submissions to post-approval studies, we offer our partners an extensive array of small molecule analytical…
Inhalation Capabilities | Why Catalent?
Summary: Catalent combines decades of project with all pulmonary dosage forms including pMDIs, DPIs, nasal sprays and solutions/suspensions for inhalation. Speed is delivered by…
RP Scherer Softgel Technology | Why Catalent?
Summary: As innovators of softgel technology, Catalent RP Scherer softgel, brings more than 75 years of development expertise and manufacturing experience to the full spectrum…
Zydis® Oral Fast Dissolve | Why Catalent?
Summary: The Zydis® ODT fast-dissolve formulation, is a unique, freeze-dried oral solid dosage form that disperses instantly in the mouth – no water required. With more than 20 products launched…
Orphan Development Capabilities | Why Catalent?
Summary: Accelerated regulatory pathways of fast track and breakthrough designations can often shave years off the approval process. Accelerating the development and approval of many drugs is often in everyone’s interest…
RP Scherer Softgel Heritage | Why Catalent?
Summary: As innovators of softgel technology, Catalent RP Scherer softgel brings more than 75 years of development expertise and manufacturing experience to the full spectrum of drug…
Reliably Supplied | Why Catalent?
Summary: We have the technology and expertise to take your product from design, to clinical trial, to plant, to pharmacy. Our global network of facilities can provide scalable, cost-effective…
Potent Handling Capabilities | Why Catalent?
Summary: Catalent is the #1 Drug Development, Delivery and Supply Partner for the global pharmaceutical and biotech industries. With over 20 years of experience in potent handling and more…
Catalent Zydis Fast Dissolve
Summary: Zydis®, our proprietary fast-dissolve technology, is a unique, freeze-dried oral solid dosage form that disperses instantly in the mouth – no water required. With more than…
Softgel Technology to Deliver Poorly Soluble APIs | Catalent in 90 Seconds
Summary: The number of poorly soluble new drugs entering development has been estimated to be anywhere from 40% to 70%. Many companies are increasingly focusing their attention on the properties…
OptiShell Technology Solves Bioavailability Challenges | Catalent in 90 Seconds
Summary: OptiShell™ capsules utilize a patented shell derived from plant polysaccharides that are ideally suited for the encapsulation of higher melting point fill formulations. Soft capsules containing semi-solid…
Catalent in 30 Seconds
Summary: With over 80 years serving the industry, Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products….
Optimal Drug Delivery Technologies. Better Treatments.
Summary: We are your catalyst for creating better treatments. Our deep expertise in drug development, delivery and supply can help improve the bioavailability of your compound, enhance therapeutic profiles…
Catalent Corporate Overview
Summary: Catalent is the global leader in development, delivery, and supply for pharmaceuticals, biologics, and consumer health products. Integrated analytical and clinical supply services support to…
Capacity and global network enables flexible manufacturing
Summary: Learn about Catalent’s manufacturing capacity and robust global network. Accredited by 30+ global agencies, it supplies oral, sterile and inhaled products. Catalent has expertise in…
Create Patient-centric Dosage Forms with Catalent
Summary: A short video on Catalent’s expertise and technologies to help achieve target therapeutic profiles and optimize bioavailability, stability and scalability to create patient-centric…
Unlock Your Molecules Potential with Catalent
Summary: Your molecule has so much potential, we share the passion to unlock it through extensive expertise and superior formulation technologies. Learn how we have optimized thousands…
Bring Pharma, Biopharma and Consumer Health Products to Market with Catalent
Summary: A short video on how Catalent can help you develop, deliver, supply better treatments. Whether it is Pharmaceuticals, Biopharmaceuticals, Over-the-Counter, Nutritionals or Beauty Care and Cosmetics, we can…
OptiForm® Solution Suite – Fast Track Early Development | Catalent in 90 Seconds
Summary: Learn about a Fast, Flexible and Fact-based path for your molecule to progress from late-stage discovery to phase I.
Zydis® ODT – Real World Solutions for Patients
Summary: Zydis® ODT is an orally dissolving tablet formulated as for fast dissolve that requires little to no water when taking the medication. It provides an ideal dosing solution when dealing…
Careers at Catalent
Summary: Join us in our mission of bringing better treatments to patients worldwide. Allow our employees to tell you why a career at Catalent could be the right opportunity…
Catalent Pharma Solutions – Be Global
Summary: Hear how our employees impact people’s lives on a global scale every day.
Career Growth and Development at Catalent
Summary: Learn from our employees how Catalent helped them grow and develop their careers.
Impacting Patient’s Lives Through Operations Careers at Catalent
Summary: Meet Cristina, one of our Operations managers, and hear about her experience working at Catalent.
Preclinical Techniques for Successful Drug Development
Summary: In this video series, P.Y. Chen, Ph.D., of Catalent Pharma Solutions offers insights for accelerating early drug development and mitigating risk. Expert insight…
Mitigating Risks During Preclinical Development
Summary: In this video series, P.Y. Chen, Ph.D., of Catalent Pharma Solutions offers insights for accelerating early drug development and mitigating risk. An expert’s view on various tools available to…
Ensuring Client’s Success in Early Drug Development
Summary: In this video series, P.Y. Chen, Ph.D., of Catalent Pharma Solutions offers insights for accelerating early drug development and mitigating risk. Learn how Catalent can….
Join Catalent in Bringing Better Treatments to Patients Worldwide
Summary: At Catalent, you will have numerous opportunities to take personal initiative, thrive in a dynamic environment, and make an impact. Allow our employees to tell you about life at Catalent and…
Dry Powder Inhaler (DPI) Services at Catalent
Summary: Catalent Inhalation provides flexible development and manufacturing solutions for Dry Powder Inhalers (DPIs).
Metered Dose Inhaler (MDI) Services at Catalent
Summary: Catalent Inhalation provides state-of-the-art development and manufacturing solutions for Metered Dose Inhalers (MDIs).
Nasal Spray Manufacture at Catalent
Summary: Catalent Inhalation provides robust development and manufacturing solutions for nasal sprays.
Overview: Catalent’s Early Talent Programs
Summary: Catalent offers numerous opportunities for students and recent grads including Internships, Co-ops, and rotational programs. Learn more!
Meet Aileen B. – GOLD Graduate
Summary: The Catalent GOLD (Global Organization Leadership Development) Program is a two-year rotational development opportunity…
Diversity & Inclusion at Catalent
Summary: At Catalent, we foster an environment where individuals are welcomed, appreciated, heard and respected, where differences and similarities are valued. Hear what our employees have to say about…
LEARN Employee Resource Group
Summary: Catalent strives to foster a diverse and inclusive environment for all employees. Learn more about our LEARN (LGBTQ+ Employees and Allies Resource Network) Employee…
Catalent Cares – Erica’s Story
Summary: Catalent supports employees who are passianate about a cause or helping the community. Hear how Catalent supported Erica and her team to raise money…
Career Development at Catalent
Summary: Catalent offers employees numerous opportunities for development and career progression. Hear more about what our team has to say about how Catalent supports their…
Product Development Careers at Catalent
Summary: Members of our product development eam gain unparalleled experience working on several products using multiple technologies. Hear what it’s like to work…
Catalent Cares – Mike’s Story
Summary: Catalent encourages employees to make a difference in their local communities. Hear how Mike and his family made a difference for children with special needs at.…
Zydis® ODT Consistently Offers Effective Solutions for Sublingual Allergy Immunotherapy
Summary: ALK-Abelló A/S is a Denmark-based pharmaceutical company that specializes in the development of immunotherapy products for the treatment of respiratory allergies. ALK partnered with Catalent for…
Flexible Manufacturing Strategies: What’s Best For Your Product?
Summary: Watch this webinar to get insight from manufacturing experts on the benefits of end-to-end solutions and how flexible manufacturing strategies can accommodate the changing landscape of the pharmaceutical industry.
Drug Product Manufacturing Infocard
Summary: Catalent can formulate and fill your product into vial, syringe, or cartridge injectable formats that are ready-to-use (RTU) for the patient or healthcare professional…
Evolution of Container Closure Integrity Testing
Summary: The USP general chapter “Package Integrity Evaluation – Sterile Product” deeply changes the way it considers the Container Closure Integrity Testing (CCIT) within the pharmaceutical…
Expediting Path to Clinic with OptiForm® Total Supply
Summary: MGB Biopharma, a biotech company based in Scotland, U.K. was developing a new class of anti-infective medicine based on Minor Groove Binder compounds. Learn how Catalent provided integrated formulation…
Primary Packaging
Summary: Planning for a clinical supply project? Having a well-thought out packaging design strategy is crucial. Download the eBook today to get expert insights on the best packaging strategies to solve stability and blinding concerns…
Managing Risks to Time Critical Product Imports at Clinical Supply Depots
Summary: A Catalent customer wanted to run a clinical trial in Israel and was arranging to ship their clinical trial product from a non-Catalent facility in Europe to a Catalent-managed and audited depot in Israel. With the protocol based…
Beyond HPLCs: Advanced Analytical Tools for the Development and Analysis of Drug Products
Summary: Advanced analytical techniques can provide timely insights into a product’s stability, performance, and composition. Download this webinar to get expert insights on the applications of analytical techniques to help answer various questions…
An Integrated Approach to Spray Drying – From Scale-up to Manufacturing
Summary: The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. Nearly 40% of the new chemical entities (NCEs) screened by pharmaceutical…
Unlock Industry Perspectives on the Advantages and Challenges of Developing Advanced Dosage Forms
Summary: Watch the webinar to learn about the tools and technologies for creating dosage forms such as orally disintegrating tablets (ODTs), multi-particulates, and modified release formulations.
Strategies To Develop Lipid-Based Drug Delivery Systems And Oral Dosage Forms
Summary: Liquid-filled capsules (LFC) are the primary delivery platform for oral delivery of lipid formulations which includes both softgels and liquid-filled hard capsules. Liquid-in-bottle is…
Overcoming Manufacturing Challenges For Accelerated Drug Development
Summary: It has been reported that surveys of migraine patients have revealed a preference for oral medications with a rapid onset of action that leads to a resolution of their symptoms. Due to the random nature of migraine attacks..
ZYDIS® ODT Unlocks a Patient Preference for Rapid Onset in the Treatment of Migraine
Summary: It has been reported that surveys of migraine patients have revealed a preference for oral medications with a rapid onset of action that leads to a resolution of their symptoms. Due to the random nature of migraine attacks..
Why Do New Therapies Succeed Or Fail In The Marketplace?
How can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?
Patient-Focused Drug Design – A View From The R&D Front Lines
Summary: Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.
Lipid Workshop Part 1: Early Development With Lipids
Get insights on using lipid systems during early development to achieve successful formulation and patient outcomes
AAPS 2015 Posters
Catalent’s experts presented technical posters on advanced drug design, discovery, development, delivery, packaging and scale-up. Click here to download [Part 1] of the 2015 AAPS posters Click here to…
Designing Complex Release Oral Solids
Controlled and Modified Release dosage form can improve patient experience.
Elemental Impurities- Guidelines, Testing And Assessments
This eBook published by Pharmaceutical Technology provides an overview of the regulatory landscape related to elemental impurities testing, discusses the challenges of implementing ICH Q3D guidelines …
Commercial Scale-Up On Fluid Bed Wurster Coating
You will learn about a pharmaceutical company who was interested in scaling-up a multi-particulate, modified-release product to a commercial scale using fluid bed bottom-spray (Wurster) coating.
Softgel Technology For Fast-Tracked Development Programs
Summary: Given the accelerated timelines associated with expedited programs, lipid-based drug formulations, encapsulated in softgel capsules, provide an attractive option for addressing the challenges…
Inhalation Capabilities Sheet
Summary: Learn about the end-to-end capabilities of Catalent’s inhalation network, supporting the development and manufacture of formulations delivered by Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs) and unit- or bi-dose nasal sprays.
De-Risk Your Early Phase Programs
Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions
Extractables & Leachables: Understanding Container and Device Interactions
Summary: It is vital that drug products reach patients uncontaminated and unadulterated by their packaging. Extractables and leachables (E&L) are especially of concern for liquid injectable…
Better Treatments By Design
To be successful, new treatments require real-world outcomes for you, your stakeholders, and most importantly the patients.
Elemental Impurities- Guidelines, Testing and Assessments
Testing for elemental impurities in pharmaceuticals is a key risk assessment activity. This eBook published by Pharmaceutical Technology provides an overview…
Overcoming Challenges for Accelerated Development
The pharmaceutical industry has experienced a trend in the number of accelerated approval designations for drugs (e.g. orphan drugs, breakthrough therapies, accelerated approvals, and FDA priority reviews) being developed.
A View From The R&D Front Lines
Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.
The Product Development Superhighway
Pharmaceutical and biotechnology companies value streamlined services from early-phase development to clinical supply services to commercialization.
Formulation Development for Scalability
Lipid formulation and spray-dried dispersions are widely used, and proven technologies to overcome bioavailability challenges for poorly soluble molecules.
Innovative OTC Remedies for the Seasonal Flu Epidemic
We will review the current OTC remedies for cough, cold and allergy categories and discuss strategies to grow your share on shelf space with innovative dosage forms.
Is Lipid Based Formulation Best for Your Molecule?
Watch this webinar to learn the key considerations for evaluating available technologies to find the most suitable bioavailability solution.
Commonly Asked Questions About Elemental Impurities
Read the latest article published by Pharmaceutical Technology giving an overview of elemental impurities testing and elemental impurities risk assessment process.
Planning Successful Launches
Read this article published by Pharmaceutical technology to learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools.
Exploring Barriers and Facilitators to Drug Launch Success
Understand why new therapies fail or succeed in the market place and learn when and how to apply advanced technologies to help increase the chance of success
Sources, Effects, and the Importance of Elemental Impurities for Finished Drug Products
Elemental impurities can arise from a variety of sources, such as active pharmaceutical ingredients (API), excipients, manufacturing equipment, and primary container closure systems.
Value Creation in the Early Phase
Strategies companies can use to succeed in both advancing their candidates and attracting investors
Strategies for Solid Form Discovery & Development
Solid form screening and selection is an integral part of drug development.
De-Risking and Accelerating Oral Drug Development
This article outlines the preclinical studies to assess and manage developability risks of NMEs for oral drug products
Quality by Design Approach to Analytical Method Optimization
Quality by Design (QbD) is well established in the pharmaceutical industry for manufacturing processes, including active pharmaceutical ingredients and drug products.
Streamline Early Drug Development
How to create a development strategy that bridges gaps earlier in the process to make the transition smoother.
The Role of Roller Compaction in Dose Design
Roller compaction is a popular dry granulation process with some significant advantages over wet granulation processes.
Using Lipid Based Delivery For Early Phase Development
Lipid-based drug delivery systems provide a reliable solution for poorly soluble molecules
Particle Size Reduction
Characterization of the micronized drug is important to understand its bulk properties and design downstream processes and manufacturing approaches.
The Truths and Myths of LBDDS
Clarifying the myths surrounding LBDSS which may make drug developers consider it in parallel to other formulation approaches
Data-Driven Risk Assessment
Developers are looking for ways to predict and overcome potential issues of new molecular entities
Phase Appropriate Stability Studies
Stability is a critical quality attribute of pharmaceutical products
Oral Solid Dose Manufacturing
Current critical issues facing the oral solid dose manufacturing industry
Formulation Design in Oral GLP Toxicology Studies
Read this article and learn about focus areas in the early drug development process that are critical for a successful toxicology study.
Dysphagia Dose Design
Gain more knowledge on dysphagia, which is one of the major factors affecting medication adherence and proper medication administration.
Scale-up of Wurster Process
Learn more about Wurster Process at Catalent Winchester.
Commercial Scale-Up on Fluid Bed Wurster Coating
Read this case study on commercial scale-up on fluid bed wurster coating.
PBPK Modeling and Other Strategies for Early Phase Success
Leveraging knowledge about an API’s physiochemical properties from preformulation and formulation studies increases the chances of early-phase success.
Next Generation of Small Molecule Oral Drugs
A connected, data-driven approach to managing bioavailability challenges in new chemical entities
Pediatric Patient Considerations During Dose Development
Developing specific dosing guidelines and acceptable dosage forms for pediatric patients to optimize therapeutic efficacy and limit and prevent serious adverse side effects.
Overcoming Technology Transfer Challenges
The key to a successful tech transfer is for the vendor and the contract manufacturer to anticipate the challenges and come up with a game plan for the solutions to potential challenges.
The Importance of Assessing Elemental Impurities
Developing a tailored package of analysis to ensure compliance with regulatory guidelines.
Expanding Your OTC Brand
Innovative dose forms to expand and improve your product line.
Dose Design: Bridging Early- And Late-Phase Development
This webcast discusses key concepts that should be addressed as a molecule advances through the clinical development phases
Risk Assessment & Test Requirements for Elemental Impurities
Selecting the best risk assessment and analytical testing strategy is key to successful compliance with the new regulations.
Best Practices for Identifying Development Candidates
The use of Pre-clinical tools to study pharmacokinetics, choose a lead drug candidate and move that product into development.
Phase Appropriate Stability Studies
Regulatory requirements and technical challenges for stability studies vary depending on the phase of the program, the intended market and the product type.
Strong Partnership Environment Heralds Success in Pharma
Will Downie, Senior Vice President, Global Sales and Marketing at Catalent, explains how his company makes a success of this strategy
Putting The Patient First When Manufacturing OSD Forms
Expert insights on ODT challenges and solutions from European Pharma Manufacturing.
Technical Guide for Solid Dispersion Development
Get the steps involved in the development and manufacturing of an ASD via the spray drying process.
Pediatric Patient Considerations During Dose Development
Learn the key considerations for developing a new drug for pediatric patients.
Elemental Impurities in the Pharmaceutical Industry
Key insights on guidelines, testing requirements, and analytical approaches for complying with the USP requirements for instrument-based heavy metals testing.
The Formulation Complex
Tips and advice on overcoming the most common formulation mishaps and why beginning with the end in mind is crucial.
From Candidate to Clinic
Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase.
Dose Selection Using Preclinical PK Modeling
How pre-clinical tools used in the industry to study pharmacokinetics are used to guide the development of new chemical entities (NCEs).
Delivering the Right Drug Candidate in the Early Phase
The key considerations for transitioning a molecule from discovery to Phase 1.
Design & Formulation for GLP Toxicology Studies
Evaluate critical areas in the drug development process to help ensure a successful toxicology study.
Review and Analysis of FDA Approved Drugs Using Lipids
A review and quantitative analysis of the molecular properties of approved drugs formulated as lipid systems
Overcome Bioavailability Challenges with Lipid Drug Delivery
How to apply lipid based formulation and encapsulate in softgel capsules for a poorly soluble molecule.
Bioavailability Enhancement Through Spray Dried Dispersions
The key spray dried dispersion (SDD) development considerations to enhance and sustain in-vivo drug solubility.
Catalent Spray Drying Technology
A holistic approach to the development and manufacture spray dried dispersions.
Bioavailability Enhancement through Spray Dried Dispersions
The key spray dried dispersion (SDD) development considerations to enhance and sustain in-vivo drug solubility.
Let the Molecule Decide
Each new drug is unique and deserves a fresh approach to formulation.
Designing Complex Release Oral Solids
Controlled and Modified Release dosage form can improve patient experience.
Tech Talks with Catalent – Spray Drying Technology
Successful spray drying process for clinical and commercial production.
Smart Drug Development & Design from Candidate to Phase I
Key considerations for transitioning a molecule from discovery to phase 1 readiness
Data-Driven Approach to Overcome Bioavailability Challenges
Unbiased & data-driven approach to select bioavailability enhancement technology.
Optiform® Solution Suite
Quick facts about OptiForm® Solution Suite
Customized Manufacturing
Customize and unique manufacturing solutions to manufacture your drug.
Optimizing Clinical Outcomes for Challenging Molecules
How lipid-based drug delivery systems (LBDDS) can be used as a bioavailability enhancing technology.
Solid Dose Trends
How the industry’s most stable drug form is innovating and evolving to stay relevant.
Formulating Candidates with Bioavailability Issues
How formulation screening early in the process can reduce development timelines.
Optimizing Speed To Market With Flexible Manufacturing Process
Get the seven steps to implement a new manufacturing technology.
Improve Patient Experience and Therapeutic Outcomes
Advanced formulation and drug delivery technologies for patient-centric drug design.
Developing Oral Dosage Forms
Agnostic & data-driven approach for early stages to find optimal formulation technology
The Challenges in Developing Therapeutic Cannabis
Development of Cannabis- based drugs can offer a consistent, reliable dose with minimal side effects.
Customized Manufacturing Solutions
Summary: Manufacturing pharmaceutical, biologic and consumer health products is becoming ever more challenging. With more complex molecules, accelerated timelines, global requirements and regulatory…
Expedite Early Drug Development
How pre-formulation techniques can accelerate early phase development to PK and first-in-human studies.
Orally Disintegrating Tablets- A Patient-Centric Dosage Form
Discover how orally disintegrating tablets (ODTs) can be both patient friendly and offer numerous formulation advantages.
Importance of Defining & Characterizing Solid State Forms
The effect of salt form selection and polymorphic screening on formulation development.
Pediatric Drug Delivery Challenges and Solutions
Key development challenges and promising technologies for delivering pediatric formulations.
Preclinical & First-in-Human Development Strategies
Crucial factors to transform a pre-clinical compound into a first-in-human candidate.
Oral Delivery of Macromolecule Drugs for Localized Treatment
Latest formulation approaches on enabling oral route for macromolecule drugs for local treatment.
Early-Phase Pharmaceutical Development Strategies
Insight on early development, characterizing solid state forms and first-in-human strategies.
Considering Patient’s Voice in Drug Design
Strategies on incorporating patient opinion into early drug design and boost patient adherence.
Trends in Manufacturing of Specialty Products
A guide on creating flexible and custom manufacturing solutions for speciality products.
Advances in Manufacturing Technology
Technology management approach & process capabilities for reliable supply of drug products.
Flexible Manufacturing Gets Pharma Products to Market Faster
Designing state-of-the-art facilities and suites address customers’ current and future needs.
Strategic Approach for Manufacturing Solid Dosage Forms
Unique roller compaction platform designed to achieve clinical and commercial success.
Preclinical & First-in-Man Drug Development Strategies
Methods for developing a sound, phase-appropriate formulation for early development.
Improve Your Phase I Success Rate
A parallel formulation feasibility assessment approach to enhance bioavailability.
ODT: A Patient-Centric Dosage Form
Discover new developments in ODT technology including delivery of peptides and vaccines.
Facilities and Operational Investment
A systematic approach to tech transfers and how to focus on technical expertise & flexibility.
Best of Pharma Manufacturing 2016
Explore the most-read articles from 2016, chosen by the Pharmaceutical Manufacturing audience.
Lipid Workshop Part 2: Expanding Lipid Formulation Platform
Latest softgel technology for targeted and controlled delivery of challenging molecules.
Lipid Workshop Part 1: Early Development With Lipids
Softgel technology for early development to achieve successful formulation and patient outcomes.
Softgel: Shapes and Sizes
Softgel technology has been increasingly applied across a wide range of applications including prescription medicines, consumer health, vitamins & mineral supplements and cosmetics.
AAPS 2016 Presentations
Discover the latest solutions and advancement in drug delivery technologies.
Particle Size Reduction to Improve Drug Performance
Create market differentiation and enable products that meet the specific medical needs of individual patients.
Improved Bioavailability of Trio Medicines TML-2
Utilize OptiForm Solution Suite to provide options for candidate formulations with extensive supporting data.
Brochure: Development Solutions
A toolkit of superior technologies to overcome all your molecule’s challenges and processing difficulties to get the optimal dosage form.
Overcome Barriers to Non-invasive Delivery Of Macromolecules
Innovative, integrated approach to rapidly screen biomolecules potential for oral delivery.
A Dosage Form Designed for Difficult Patient Populations
Explore how orally disintegrating tablets (ODTs) provide an alternative to overcome several challenges.
A Holistic Approach for Drug Development and Delivery
How can a patient-centric outlook help scientists tackle the key challenges of early drug development.
Advances in Manufacturing Technology
Improve the efficiency, reliability, flexibility & speed to market for your next manufacturing process.
Thinking Small
Enhance bioavailability & efficacy while reducing adverse effects with particle size reduction.
New Approaches to De-risking Early Drug Development
Insights on how to pick the right candidates for clinical development & revamping projects.
Unlock Oral Delivery Potential for Macromolecules
Effectively evaluate the potential of peptides and macromolecules for oral delivery.
Optimize Dosage Form for Patient-Centric Drug-Development
Strategies & technologies which can minimize the risks of developing new drugs and more.
Innovative Drug Delivery Technologies for Better Treatments
Better patient treatments fueled by innovations in lipid formulations.
How Parallel Development with Proven Technologies Improves
Efficiently and rapidly overcome complex bioavailability challenges for early stage molecules.
Enhance Bioavailability with Parallel Screening Technologies
Characterize molecules, apply right prediction model, & select ideal delivery technology.
The Soft Side of Drug Delivery
Discover an innovative way to deliver challenging and poorly soluble compounds.
OptiShell™ Technology for the OTC Market
Innovative solution for overcoming encapsulation challenges for OTC products.
Patient-centric Dose Design
Avoid some of the limitations of conventional tablet dose forms & more.
The Versatile Orodispersable Tablet (ODT) Technology
ODT platform ideal for sublingual delivery of proteins, peptides & vaccines.
LBDDS to Bring Poorly Soluble Drugs to Market
Address compounds early on in the development process to reduce costs & attrition rates.
Keys to Successful Technology Transfers
Ensure your technology transfers meet scheduled timelines.
Versatility of Micronization for Bioavailability Enhancement
Explores the benefits of co-micronization with a surfactant and cryogenic micronization.
Critical Process Parameters of an API via Micronization
Understand the logistics of commercial manufacturing using design of experiments (DOE).
The Medicine Maker – Bioavailability by Design
Address bioavailability challenges faced in biologic development with a focus on oral delivery.
Oral Dose Development of Macromolecules
Discover new approach to optimize oral dose development for macromolecules.
Optimal Formulation Technology for Better Patient Treatment
Strategies for oral formulation selection which can lower attrition rates and more.
Handling Highly Potent Materials Safely
Have a rigorous and carefully designed plan as to how to handle the compounds safely.
Graphicaps™ Inline Printing
Differentiate products at the unit dose level & deliver a more recognizable product.
The Next Generation ODT
New developments in ODT technology, including new ways to administer peptides & vaccines.
Overcoming Challenges In Generic pMDI Development
Define key aspects of product performance which must be met when developing a generic pMDI.
Parallel Screening for Non-Invasive Macromolecule Delivery
Integrated solutions to rapidly screen biomolecules potential for non-invasive delivery route.
Strategies To Overcome Development Challenges
Address development challenges early on and improve a drug’s path to market.
Accelerate Development for Challenging Compounds
Leverage solid dispersion & particle size reduction technology to enhance bioavailability.
Roadmap for Successful Technology Transfer
Make the right decisions to ensure a successful technology transfer.
Holistic Approach To High Potency API Operations
Mitigate cross-contamination risk and regulatory issues.
Novel Technologies To Deliver Oral Oncology Therapies
Select optimal formulation technology to enhance therapeutic performance & patient experience.
Optimizing API Properties And Formulation
Utilize particle size reduction and formulation technologies to optimize the API.
Overcome Formulation Challenges & Gain Customer Acceptance
Enhance bioavailability, deliver liquid APIs & more with softgel technology.
Softgel Technologies to Deliver Poorly Soluble Molecules
Expedite the development pathway for early phase compounds and enhance bioavailability.
Create Effective Fast-Dissolving Oral Formulations
Successfully manufacture oral dosage forms that disperse within 3 seconds & are enjoyable.
Catalent Innovations, Trends and New Technologies
Boost bioavailability, improve ease & route of administration, and increase patient compliance.
The Medicine Maker – Deep Breaths and Dry Powder
Explore the challenges with delivering drugs less invasively.
Drug Manufacturing Solutions in a Complex Industry
Address unique program requirements with flexible manufacturing solutions.
Accelerated Bioavailability for Early Phase Molecules
Increase the dissolution rates of poorly water-soluble drugs to increase bioavailability.
Addressing Early Phase Development Challenges
Increase patient adherence while reducing reformulation time & costs.
Novel Coating Process for Taste Masking APIs
Provide the ability to taste mask & coat smaller particle size APIs.
A Structured Approach to Enhancing Bioavailability
Utilize an all-encompassing approach to enable an effective dosage form faster to market.
Optimizing Small Batch Size To Solve Formulation Challenges
Enable the formulation development of a drug molecule in softgels on industrial scale machines.
Enteric Coated Softgels for Consumer Products
Improve product performance & enhance consumer experience with enteric coating.
The Medicine Maker – Finding Optimal Form
Increase chances of success in drug development by focusing on API optimization from the start.
Bioavailability Enhancement for Early Phase Molecules
Suitable path to accelerate development, avoid risk at early phase & enhance bioavailability.
Solution Suite Accelerates Bioavailability Enhancement
Select the most suitable formulation technology to enhance the molecule’s bioavailability.
The Medicine Maker – Delivering Change
The future of non-invasive delivery technologies for large molecules.
The Medicine Maker – The Toolbox of 2025
Overcome therapeutic challenges and be prepared for years to come.
Oral Formulation Strategies and Technologies
Oral dose development with optimal therapeutic performance.
Bringing a Small Molecule to Clinic
Transition from preliminary formulation to commercial drug launch, quickly & cost-effectively.
Softgel Capsules Low Batch Size Optimize in cGMP Labs
Handle small amounts of API or formulation at the early stages of development.
Optimization of Type I & II Lipid Based Drug Delivery System
Limit individual variability of type I & II systems with adequate choice of composition.
Pharmaceutical Abuse Deterrent Capsule Formulations
Develop liquid capsule fill formulations that are mitigated to prevent abuse.
Bioavailability Toolkit to Fast Track Development
Design a safe, effective & stable dosage form, and ensure patient compliance.
Solutions for Challenging Compounds Using Softgel Innovation
Improve compatibility with wider range of excipients to enhance bioavailability & stability.
Overcoming Poor Solubility in Formulation Development
Lipid-based drug-delivery systems to assist in the delivery of poorly soluble drugs.
Overcome Early Phase Development Challenges
Perform dosage form selection in the early phases of drug development.
The Versatility of Softgel Technology
Optimize manufacturing parameters like lower processing temperature & thinner softgel shell.
New Approaches for Macromolecule Oral Delivery
The toolkit of technologies based upon lipid-based drug delivery systems.
New Technologies for Complex Oral Formulation
Drug delivery solutions need to become more sophisticated and more effective.
Early Technology Selection for Optimized Drug Development
Choose the right technology to develop an efficient Phase I enabling drug product
Formulation Development with Minimal Amount of API
Solubility screening approaches that can save both time and money.
The Bioavailability Toolbox
Scientists now have an arsenal of drug delivery techniques to choose from.
OptiGel Mini Technology
Deliver higher API concentrations in smaller capsules for patient benefits.
AAPS 2014 with Pharmaceutical Outsourcing
OptiPact™ Technology, capabilities for Orphan Drugs & Catalent’s factors of differentiation.
OptiGel Bio Enables Delivery of Synthetic Oligosaccharides
Macromolecules can potentially be converted from injectable to oral drug delivery.
Optimize Your Oral Drug Development Pathway
Learn about how softgel technologies can address API and processing challenges.
New Formulation and Delivery Technology is Unlocking Profit
Learn more about integrating formulation technology in drug development.
Lipid-Based Delivery of Peptide Therapeutics
An explanation of OptiGel Bio™ technology as a delivery tool for macromolecule NCE candidates.
Conversion from LFHS to RP Scherer Softgel Capsules
RP Scherer Technology can improve timelines and commercialization potential.
Strategies for Orphan, Breakthrough and Fast Track Programs
Learn about Orphan drug development and other fast track product development pathways.
OptiShell® Technology Capsule Innovations
New shell and hot-filling that are highly viscous or semi-solid at room temperature